25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Pfizer Inc
Buy, Hold or Sell?

Let's analyze Pfizer together

I guess you are interested in Pfizer Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pfizer Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Pfizer Inc

I send you an email if I find something interesting about Pfizer Inc.

1. Quick Overview

1.1. Quick analysis of Pfizer (30 sec.)










1.2. What can you expect buying and holding a share of Pfizer? (30 sec.)

How much money do you get?

How much money do you get?
R$0.07
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
R$4.08
Expected worth in 1 year
R$3.89
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
R$0.22
Return On Investment
0.6%

For what price can you sell your share?

Current Price per Share
R$36.34
Expected price per share
R$35.29 - R$38.42
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Pfizer (5 min.)




Live pricePrice per Share (EOD)
R$36.34
Intrinsic Value Per Share
R$-4.11 - R$-5.21
Total Value Per Share
R$-0.03 - R$-1.13

2.2. Growth of Pfizer (5 min.)




Is Pfizer growing?

Current yearPrevious yearGrowGrow %
How rich?$15.9b$16.8b-$1.2b-8.3%

How much money is Pfizer making?

Current yearPrevious yearGrowGrow %
Making money$182.8m$450.7m-$267.9m-146.5%
Net Profit Margin5.7%12.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Pfizer (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Pfizer?

Welcome investor! Pfizer's management wants to use your money to grow the business. In return you get a share of Pfizer.

First you should know what it really means to hold a share of Pfizer. And how you can make/lose money.

Speculation

The Price per Share of Pfizer is R$36.34. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pfizer.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pfizer, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is R$4.08. Based on the TTM, the Book Value Change Per Share is R$-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is R$0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is R$0.10 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pfizer.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 R$% of Price per ShareR$% of Price per ShareR$% of Price per ShareR$% of Price per ShareR$% of Price per Share
Usd Eps0.030.1%0.010.0%0.020.1%0.030.1%0.030.1%
Usd Book Value Change Per Share0.030.1%-0.010.0%0.010.0%0.010.0%0.020.1%
Usd Dividend Per Share0.020.0%0.020.0%0.030.1%0.020.1%0.020.1%
Usd Total Gains Per Share0.050.1%0.010.0%0.030.1%0.030.1%0.040.1%
Usd Price Per Share6.80-6.39-8.80-13.26-17.12-
Price to Earnings Ratio50.15-1,375.29-34.30-248.53-161.69-
Price-to-Total Gains Ratio128.62--71.01-844.53-4,531.13-3,165.81-
Price to Book Ratio9.68-9.29-11.84-23.74-33.04-
Price-to-Total Gains Ratio128.62--71.01-844.53-4,531.13-3,165.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.25048
Number of shares159
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.02
Usd Book Value Change Per Share-0.010.01
Usd Total Gains Per Share0.010.03
Gains per Quarter (159 shares)1.535.37
Gains per Year (159 shares)6.1221.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
111-5-415711
223-112301332
334-168452053
446-2114602674
557-2620753395
668-32268939116
780-373210446137
891-423811952158
9103-484413459179
10114-535014966200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%17.03.00.085.0%28.04.00.087.5%28.04.00.087.5%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%13.07.00.065.0%20.012.00.062.5%20.012.00.062.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%32.00.00.0100.0%32.00.00.0100.0%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%18.02.00.090.0%28.04.00.087.5%28.04.00.087.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Pfizer Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.202-0.048+124%0.045+353%0.060+237%0.128+58%
Book Value Per Share--4.0833.997+2%4.330-6%3.598+13%3.311+23%
Current Ratio--1.0000.954+5%1.770-43%1.350-26%1.349-26%
Debt To Asset Ratio--0.5780.590-2%0.525+10%0.574+1%0.589-2%
Debt To Equity Ratio--1.3751.443-5%1.110+24%1.369+0%1.459-6%
Dividend Per Share--0.1050.104+1%0.152-31%0.136-23%0.118-11%
Eps--0.1970.047+320%0.116+70%0.160+23%0.168+17%
Free Cash Flow Per Share--0.2670.091+195%0.090+197%0.177+51%0.177+51%
Free Cash Flow To Equity Per Share--0.0630.018+247%0.862-93%0.258-76%0.258-76%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.208--------
Intrinsic Value_10Y_min---4.109--------
Intrinsic Value_1Y_max--0.425--------
Intrinsic Value_1Y_min--0.418--------
Intrinsic Value_3Y_max--0.556--------
Intrinsic Value_3Y_min--0.545--------
Intrinsic Value_5Y_max---0.184--------
Intrinsic Value_5Y_min---0.108--------
Market Cap823755092090.880-9%895612649656.320841492801489.920+6%1159638170711.040-23%1748167434771.456-49%2256663077293.439-60%
Net Profit Margin--0.2520.057+342%0.128+97%0.190+32%0.237+6%
Operating Margin----0%0.202-100%0.254-100%0.293-100%
Operating Ratio--0.9991.173-15%1.271-21%1.116-10%1.032-3%
Pb Ratio8.900-9%9.6769.295+4%11.841-18%23.744-59%33.036-71%
Pe Ratio46.123-9%50.1461375.288-96%34.303+46%248.534-80%161.687-69%
Price Per Share36.340-9%39.51037.123+6%51.158-23%77.121-49%99.553-60%
Price To Free Cash Flow Ratio33.966-9%36.929125.951-71%1010.975-96%322.877-89%201.798-82%
Price To Total Gains Ratio118.305-9%128.625-71.008+155%844.533-85%4531.133-97%3165.810-96%
Quick Ratio--0.5390.481+12%2.215-76%1.279-58%1.104-51%
Return On Assets--0.0200.005+312%0.013+53%0.020+4%0.022-6%
Return On Equity--0.0480.011+332%0.027+83%0.045+8%0.052-7%
Total Gains Per Share--0.3070.056+449%0.197+56%0.196+57%0.245+25%
Usd Book Value--15919976000.00015582297000.000+2%16881069000.000-6%14030169000.000+13%12907621750.000+23%
Usd Book Value Change Per Share--0.035-0.008+124%0.008+353%0.010+237%0.022+58%
Usd Book Value Per Share--0.7020.687+2%0.745-6%0.619+13%0.569+23%
Usd Dividend Per Share--0.0180.018+1%0.026-31%0.023-23%0.020-11%
Usd Eps--0.0340.008+320%0.020+70%0.027+23%0.029+17%
Usd Free Cash Flow--1042836000.000353761000.000+195%351654000.000+197%656489600.000+59%410306000.000+154%
Usd Free Cash Flow Per Share--0.0460.016+195%0.016+197%0.030+51%0.030+51%
Usd Free Cash Flow To Equity Per Share--0.0110.003+247%0.148-93%0.044-76%0.044-76%
Usd Market Cap141685875839.631-9%154045375740.887144736761856.266+6%199457765362.299-23%300684798780.690-49%388146049294.472-60%
Usd Price Per Share6.250-9%6.7966.385+6%8.799-23%13.265-49%17.123-60%
Usd Profit--767980000.000182836000.000+320%450769000.000+70%622012200.000+23%656685250.000+17%
Usd Revenue--3044572000.0002584773000.000+18%2947134000.000+3%2930682200.000+4%2685672500.000+13%
Usd Total Gains Per Share--0.0530.010+449%0.034+56%0.034+57%0.042+25%
 EOD+4 -4MRQTTM+32 -2YOY+18 -175Y+22 -1310Y+22 -13

3.3 Fundamental Score

Let's check the fundamental score of Pfizer Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1546.123
Price to Book Ratio (EOD)Between0-18.900
Net Profit Margin (MRQ)Greater than00.252
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.539
Current Ratio (MRQ)Greater than11.000
Debt to Asset Ratio (MRQ)Less than10.578
Debt to Equity Ratio (MRQ)Less than11.375
Return on Equity (MRQ)Greater than0.150.048
Return on Assets (MRQ)Greater than0.050.020
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Pfizer Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose36.130
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2024-11-13 21:41:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Pfizer earns for each R$1 of revenue.

  • Above 10% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 25.2% means that R$0.25 for each R$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pfizer Inc:

  • The MRQ is 25.2%. The company is making a huge profit. +2
  • The TTM is 5.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ25.2%TTM5.7%+19.5%
TTM5.7%YOY12.8%-7.1%
TTM5.7%5Y19.0%-13.3%
5Y19.0%10Y23.7%-4.7%
4.3.1.2. Return on Assets

Shows how efficient Pfizer is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • 2.0% Return on Assets means that Pfizer generated R$0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pfizer Inc:

  • The MRQ is 2.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.5%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.0%TTM0.5%+1.5%
TTM0.5%YOY1.3%-0.8%
TTM0.5%5Y2.0%-1.5%
5Y2.0%10Y2.2%-0.2%
4.3.1.3. Return on Equity

Shows how efficient Pfizer is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • 4.8% Return on Equity means Pfizer generated R$0.05 for each R$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pfizer Inc:

  • The MRQ is 4.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.8%TTM1.1%+3.7%
TTM1.1%YOY2.7%-1.5%
TTM1.1%5Y4.5%-3.4%
5Y4.5%10Y5.2%-0.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Pfizer Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Pfizer is operating .

  • Measures how much profit Pfizer makes for each R$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated R$0.00  for each R$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pfizer Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY20.2%-20.2%
TTM-5Y25.4%-25.4%
5Y25.4%10Y29.3%-3.9%
4.3.2.2. Operating Ratio

Measures how efficient Pfizer is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.00 means that the operating costs are R$1.00 for each R$1 in net sales.

Let's take a look of the Operating Ratio trends of Pfizer Inc:

  • The MRQ is 0.999. The company is less efficient in keeping operating costs low.
  • The TTM is 1.173. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.999TTM1.173-0.174
TTM1.173YOY1.271-0.099
TTM1.1735Y1.116+0.057
5Y1.11610Y1.032+0.084
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Pfizer Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Pfizer is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.00 means the company has R$1.00 in assets for each R$1 in short-term debts.

Let's take a look of the Current Ratio trends of Pfizer Inc:

  • The MRQ is 1.000. The company is just able to pay all its short-term debts.
  • The TTM is 0.954. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ1.000TTM0.954+0.046
TTM0.954YOY1.770-0.816
TTM0.9545Y1.350-0.396
5Y1.35010Y1.349+0.001
4.4.3.2. Quick Ratio

Measures if Pfizer is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.54 means the company can pay off R$0.54 for each R$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pfizer Inc:

  • The MRQ is 0.539. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.481. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.539TTM0.481+0.058
TTM0.481YOY2.215-1.733
TTM0.4815Y1.279-0.797
5Y1.27910Y1.104+0.175
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Pfizer Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Pfizer assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pfizer to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.58 means that Pfizer assets are financed with 57.8% credit (debt) and the remaining percentage (100% - 57.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pfizer Inc:

  • The MRQ is 0.578. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.590. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.578TTM0.590-0.011
TTM0.590YOY0.525+0.065
TTM0.5905Y0.574+0.016
5Y0.57410Y0.589-0.015
4.5.4.2. Debt to Equity Ratio

Measures if Pfizer is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 137.5% means that company has R$1.38 debt for each R$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pfizer Inc:

  • The MRQ is 1.375. The company is able to pay all its debts with equity. +1
  • The TTM is 1.443. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.375TTM1.443-0.068
TTM1.443YOY1.110+0.333
TTM1.4435Y1.369+0.074
5Y1.36910Y1.459-0.090
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every R$1 in earnings Pfizer generates.

  • Above 15 is considered overpriced but always compare Pfizer to the Drug Manufacturers - General industry mean.
  • A PE ratio of 50.15 means the investor is paying R$50.15 for every R$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pfizer Inc:

  • The EOD is 46.123. Based on the earnings, the company is overpriced. -1
  • The MRQ is 50.146. Based on the earnings, the company is expensive. -2
  • The TTM is 1,375.288. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD46.123MRQ50.146-4.023
MRQ50.146TTM1,375.288-1,325.142
TTM1,375.288YOY34.303+1,340.985
TTM1,375.2885Y248.534+1,126.754
5Y248.53410Y161.687+86.848
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pfizer Inc:

  • The EOD is 33.966. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 36.929. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 125.951. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD33.966MRQ36.929-2.963
MRQ36.929TTM125.951-89.022
TTM125.951YOY1,010.975-885.023
TTM125.9515Y322.877-196.926
5Y322.87710Y201.798+121.079
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Pfizer is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 9.68 means the investor is paying R$9.68 for each R$1 in book value.

Let's take a look of the Price to Book Ratio trends of Pfizer Inc:

  • The EOD is 8.900. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.676. Based on the equity, the company is overpriced. -1
  • The TTM is 9.295. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD8.900MRQ9.676-0.776
MRQ9.676TTM9.295+0.381
TTM9.295YOY11.841-2.546
TTM9.2955Y23.744-14.449
5Y23.74410Y33.036-9.292
4.6.2. Total Gains per Share

2.4. Latest News of Pfizer Inc

Does Pfizer Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Pfizer Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-11-06
19:15
Vaccine Stocks Drop on Worries About an RFK Jr. RoleRead
2024-10-31
21:09
Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans?Read
2024-10-29
19:47
Pfizer is racing to get in on the weight loss drug boomRead
2024-10-29
17:08
Pfizer is getting another COVID-19 sales boostRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in BRL. All numbers in thousands.

Summary
Total Assets219,476,000
Total Liabilities126,918,000
Total Stockholder Equity92,286,000
 As reported
Total Liabilities 126,918,000
Total Stockholder Equity+ 92,286,000
Total Assets = 219,476,000

Assets

Total Assets219,476,000
Total Current Assets43,223,000
Long-term Assets176,254,000
Total Current Assets
Cash And Cash Equivalents 1,092,000
Short-term Investments 8,860,000
Net Receivables 14,451,000
Inventory 11,721,000
Other Current Assets 3,856,000
Total Current Assets  (as reported)43,223,000
Total Current Assets  (calculated)39,980,000
+/- 3,243,000
Long-term Assets
Property Plant Equipment 18,541,000
Goodwill 68,570,000
Long Term Investments 10,762,000
Intangible Assets 59,986,000
Long-term Assets Other 10,486,000
Long-term Assets  (as reported)176,254,000
Long-term Assets  (calculated)168,345,000
+/- 7,909,000

Liabilities & Shareholders' Equity

Total Current Liabilities43,211,000
Long-term Liabilities83,707,000
Total Stockholder Equity92,286,000
Total Current Liabilities
Short Long Term Debt 9,699,000
Accounts payable 5,314,000
Other Current Liabilities 19,918,000
Total Current Liabilities  (as reported)43,211,000
Total Current Liabilities  (calculated)34,931,000
+/- 8,280,000
Long-term Liabilities
Long term Debt 56,918,000
Long-term Liabilities Other 15,570,000
Long-term Liabilities  (as reported)83,707,000
Long-term Liabilities  (calculated)72,488,000
+/- 11,219,000
Total Stockholder Equity
Retained Earnings 121,059,000
Total Stockholder Equity (as reported)92,286,000
Total Stockholder Equity (calculated)121,059,000
+/- 28,773,000
Other
Capital Stock480,000
Common Stock Shares Outstanding 5,666,000
Net Debt 65,525,000
Net Invested Capital 158,903,000
Net Working Capital 12,000
Property Plant and Equipment Gross 35,216,000



6.2. Balance Sheets Structured

Currency in BRL. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
171,615,000
168,784,000
168,558,000
172,151,000
171,797,000
164,612,000
164,980,000
167,838,000
159,422,000
155,421,000
156,199,000
170,446,000
167,489,000
166,336,000
177,934,000
178,983,000
154,229,000
158,818,000
169,920,000
179,188,000
181,476,000
183,841,000
195,290,000
195,350,000
197,205,000
195,617,000
220,168,000
215,021,000
226,501,000
221,095,000
216,193,000
219,476,000
219,476,000216,193,000221,095,000226,501,000215,021,000220,168,000195,617,000197,205,000195,350,000195,290,000183,841,000181,476,000179,188,000169,920,000158,818,000154,229,000178,983,000177,934,000166,336,000167,489,000170,446,000156,199,000155,421,000159,422,000167,838,000164,980,000164,612,000171,797,000172,151,000168,558,000168,784,000171,615,000
   > Total Current Assets 
38,949,000
35,878,000
36,385,000
40,291,000
41,142,000
34,835,000
37,303,000
41,583,000
49,926,000
45,290,000
47,073,000
33,459,000
32,803,000
34,738,000
46,424,000
47,739,000
35,067,000
39,533,000
48,814,000
57,900,000
59,693,000
54,420,000
67,466,000
70,403,000
51,259,000
50,078,000
73,347,000
74,012,000
43,333,000
42,415,000
37,825,000
43,223,000
43,223,00037,825,00042,415,00043,333,00074,012,00073,347,00050,078,00051,259,00070,403,00067,466,00054,420,00059,693,00057,900,00048,814,00039,533,00035,067,00047,739,00046,424,00034,738,00032,803,00033,459,00047,073,00045,290,00049,926,00041,583,00037,303,00034,835,00041,142,00040,291,00036,385,00035,878,00038,949,000
       Cash And Cash Equivalents 
2,595,000
4,057,000
2,585,000
2,779,000
1,342,000
2,302,000
2,704,000
3,559,000
1,139,000
1,937,000
1,784,000
2,785,000
1,305,000
2,151,000
1,801,000
1,587,000
1,784,000
1,768,000
2,372,000
1,966,000
1,944,000
2,470,000
1,780,000
1,298,000
416,000
2,166,000
2,632,000
3,148,000
2,853,000
719,000
1,052,000
1,092,000
1,092,0001,052,000719,0002,853,0003,148,0002,632,0002,166,000416,0001,298,0001,780,0002,470,0001,944,0001,966,0002,372,0001,768,0001,784,0001,587,0001,801,0002,151,0001,305,0002,785,0001,784,0001,937,0001,139,0003,559,0002,704,0002,302,0001,342,0002,779,0002,585,0004,057,0002,595,000
       Short-term Investments 
15,255,000
10,503,000
11,748,000
14,146,000
18,650,000
9,078,000
10,685,000
13,680,000
17,694,000
9,682,000
11,128,000
6,302,000
8,525,000
8,199,000
9,581,000
8,912,000
10,437,000
11,899,000
19,328,000
27,730,000
29,125,000
21,427,000
31,524,000
34,825,000
22,316,000
17,806,000
42,153,000
41,033,000
9,837,000
11,210,000
6,049,000
8,860,000
8,860,0006,049,00011,210,0009,837,00041,033,00042,153,00017,806,00022,316,00034,825,00031,524,00021,427,00029,125,00027,730,00019,328,00011,899,00010,437,0008,912,0009,581,0008,199,0008,525,0006,302,00011,128,0009,682,00017,694,00013,680,00010,685,0009,078,00018,650,00014,146,00011,748,00010,503,00015,255,000
       Net Receivables 
11,266,000
11,683,000
12,589,000
13,265,000
11,271,000
13,076,000
13,455,000
13,710,000
11,399,000
9,599,000
9,793,000
9,439,000
12,068,000
9,881,000
9,128,000
10,012,000
7,930,000
9,864,000
14,348,000
15,774,000
15,745,000
16,342,000
17,738,000
18,620,000
14,529,000
15,445,000
13,425,000
11,086,000
11,177,000
10,989,000
11,393,000
14,451,000
14,451,00011,393,00010,989,00011,177,00011,086,00013,425,00015,445,00014,529,00018,620,00017,738,00016,342,00015,745,00015,774,00014,348,0009,864,0007,930,00010,012,0009,128,0009,881,00012,068,0009,439,0009,793,0009,599,00011,399,00013,710,00013,455,00013,076,00011,271,00013,265,00012,589,00011,683,00011,266,000
       Inventory 
6,783,000
7,415,000
7,680,000
8,017,000
7,578,000
8,148,000
8,074,000
8,184,000
7,508,000
8,029,000
8,233,000
8,222,000
8,283,000
8,423,000
8,564,000
9,295,000
8,046,000
8,493,000
8,948,000
8,640,000
9,059,000
9,979,000
10,454,000
9,513,000
8,981,000
9,541,000
10,310,000
10,204,000
10,189,000
10,892,000
11,447,000
11,721,000
11,721,00011,447,00010,892,00010,189,00010,204,00010,310,0009,541,0008,981,0009,513,00010,454,0009,979,0009,059,0008,640,0008,948,0008,493,0008,046,0009,295,0008,564,0008,423,0008,283,0008,222,0008,233,0008,029,0007,508,0008,184,0008,074,0008,148,0007,578,0008,017,0007,680,0007,415,0006,783,000
       Other Current Assets 
3,050,000
2,221,000
1,677,000
1,987,000
2,197,000
2,138,000
2,287,000
2,362,000
12,089,000
2,568,000
2,535,000
2,952,000
2,569,000
6,084,000
17,350,000
17,933,000
6,870,000
7,509,000
3,816,000
3,784,000
3,816,000
4,197,000
5,962,000
6,138,000
5,017,000
5,120,000
4,827,000
4,624,000
5,299,000
4,372,000
4,190,000
3,856,000
3,856,0004,190,0004,372,0005,299,0004,624,0004,827,0005,120,0005,017,0006,138,0005,962,0004,197,0003,816,0003,784,0003,816,0007,509,0006,870,00017,933,00017,350,0006,084,0002,569,0002,952,0002,535,0002,568,00012,089,0002,362,0002,287,0002,138,0002,197,0001,987,0001,677,0002,221,0003,050,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
110,132,000
109,126,000
136,987,000
134,685,000
131,599,000
131,511,000
131,245,000
119,163,000
119,284,000
121,106,000
121,288,000
121,782,000
129,420,000
127,824,000
124,946,000
145,944,000
145,539,000
146,822,000
141,009,000
183,168,000
178,680,000
178,367,000
176,254,000
176,254,000178,367,000178,680,000183,168,000141,009,000146,822,000145,539,000145,944,000124,946,000127,824,000129,420,000121,782,000121,288,000121,106,000119,284,000119,163,000131,245,000131,511,000131,599,000134,685,000136,987,000109,126,000110,132,000000000000
       Property Plant Equipment 
13,318,000
13,238,000
13,386,000
13,505,000
13,865,000
13,971,000
13,919,000
14,036,000
13,385,000
14,747,000
14,794,000
15,007,000
15,280,000
14,040,000
14,113,000
14,403,000
15,293,000
14,011,000
14,224,000
14,436,000
17,721,000
15,109,000
15,244,000
15,441,000
16,274,000
17,052,000
17,488,000
17,862,000
18,940,000
18,803,000
18,957,000
18,541,000
18,541,00018,957,00018,803,00018,940,00017,862,00017,488,00017,052,00016,274,00015,441,00015,244,00015,109,00017,721,00014,436,00014,224,00014,011,00015,293,00014,403,00014,113,00014,040,00015,280,00015,007,00014,794,00014,747,00013,385,00014,036,00013,919,00013,971,00013,865,00013,505,00013,386,00013,238,00013,318,000
       Goodwill 
54,449,000
54,656,000
55,014,000
56,078,000
55,952,000
56,393,000
55,836,000
55,614,000
53,411,000
53,487,000
53,352,000
58,665,000
58,653,000
58,502,000
58,449,000
59,902,000
49,577,000
49,791,000
49,867,000
49,489,000
49,208,000
50,211,000
49,891,000
49,441,000
51,375,000
51,476,000
51,572,000
51,527,000
67,783,000
69,297,000
68,445,000
68,570,000
68,570,00068,445,00069,297,00067,783,00051,527,00051,572,00051,476,00051,375,00049,441,00049,891,00050,211,00049,208,00049,489,00049,867,00049,791,00049,577,00059,902,00058,449,00058,502,00058,653,00058,665,00053,352,00053,487,00053,411,00055,614,00055,836,00056,393,00055,952,00056,078,00055,014,00054,656,00054,449,000
       Long Term Investments 
7,116,000
7,346,000
7,542,000
7,843,000
7,492,000
7,197,000
6,819,000
6,631,000
3,047,000
2,859,000
2,905,000
18,722,000
20,147,000
18,220,000
18,720,000
19,008,000
20,262,000
20,228,000
20,942,000
21,597,000
21,526,000
20,737,000
18,963,000
13,888,000
15,069,000
14,743,000
15,066,000
14,238,000
15,368,000
11,613,000
11,148,000
10,762,000
10,762,00011,148,00011,613,00015,368,00014,238,00015,066,00014,743,00015,069,00013,888,00018,963,00020,737,00021,526,00021,597,00020,942,00020,228,00020,262,00019,008,00018,720,00018,220,00020,147,00018,722,0002,905,0002,859,0003,047,0006,631,0006,819,0007,197,0007,492,0007,843,0007,542,0007,346,0007,116,000
       Intangible Assets 
52,648,000
52,427,000
51,348,000
49,721,000
48,741,000
47,690,000
46,584,000
45,306,000
35,211,000
34,040,000
33,025,000
38,995,000
35,369,000
34,464,000
33,541,000
30,927,000
28,471,000
27,974,000
27,323,000
26,306,000
25,146,000
29,816,000
29,065,000
28,150,000
43,370,000
42,002,000
41,406,000
40,224,000
64,900,000
62,828,000
61,240,000
59,986,000
59,986,00061,240,00062,828,00064,900,00040,224,00041,406,00042,002,00043,370,00028,150,00029,065,00029,816,00025,146,00026,306,00027,323,00027,974,00028,471,00030,927,00033,541,00034,464,00035,369,00038,995,00033,025,00034,040,00035,211,00045,306,00046,584,00047,690,00048,741,00049,721,00051,348,00052,427,00052,648,000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
4,333,000
4,388,000
4,920,000
4,450,000
4,166,000
4,327,000
4,355,000
4,569,000
4,744,000
6,056,000
6,705,000
7,679,000
7,879,000
7,659,000
10,890,000
13,163,000
12,965,000
13,028,000
8,808,000
12,471,000
11,197,000
10,710,000
10,486,000
10,486,00010,710,00011,197,00012,471,0008,808,00013,028,00012,965,00013,163,00010,890,0007,659,0007,879,0007,679,0006,705,0006,056,0004,744,0004,569,0004,355,0004,327,0004,166,0004,450,0004,920,0004,388,0004,333,000000000000
> Total Liabilities 
112,072,000
110,349,000
109,864,000
111,041,000
100,141,000
94,070,000
94,857,000
96,174,000
95,664,000
96,263,000
96,275,000
105,050,000
104,042,000
101,310,000
113,598,000
113,724,000
90,991,000
90,198,000
99,605,000
103,221,000
104,276,000
101,156,000
107,821,000
102,459,000
101,545,000
94,647,000
121,149,000
118,087,000
137,213,000
128,537,000
128,218,000
126,918,000
126,918,000128,218,000128,537,000137,213,000118,087,000121,149,00094,647,000101,545,000102,459,000107,821,000101,156,000104,276,000103,221,00099,605,00090,198,00090,991,000113,724,000113,598,000101,310,000104,042,000105,050,00096,275,00096,263,00095,664,00096,174,00094,857,00094,070,000100,141,000111,041,000109,864,000110,349,000112,072,000
   > Total Current Liabilities 
31,115,000
24,864,000
27,182,000
28,217,000
30,427,000
27,365,000
32,156,000
29,013,000
31,858,000
29,423,000
32,030,000
36,974,000
37,304,000
33,890,000
32,723,000
34,154,000
25,920,000
26,652,000
35,664,000
41,803,000
42,671,000
39,268,000
47,410,000
44,314,000
42,138,000
36,562,000
34,647,000
31,136,000
47,794,000
40,497,000
43,819,000
43,211,000
43,211,00043,819,00040,497,00047,794,00031,136,00034,647,00036,562,00042,138,00044,314,00047,410,00039,268,00042,671,00041,803,00035,664,00026,652,00025,920,00034,154,00032,723,00033,890,00037,304,00036,974,00032,030,00029,423,00031,858,00029,013,00032,156,00027,365,00030,427,00028,217,00027,182,00024,864,00031,115,000
       Short-term Debt 
10,688,000
7,680,000
43,871,000
3,073,000
3,547,000
4,765,000
4,273,000
4,264,000
4,781,000
9,410,000
10,506,000
16,617,000
16,195,000
15,670,000
11,603,000
11,214,000
701,000
676,000
201,000
966,000
605,000
0
0
1,474,000
395,000
621,000
420,000
298,000
0
0
0
0
0000298,000420,000621,000395,0001,474,00000605,000966,000201,000676,000701,00011,214,00011,603,00015,670,00016,195,00016,617,00010,506,0009,410,0004,781,0004,264,0004,273,0004,765,0003,547,0003,073,00043,871,0007,680,00010,688,000
       Short Long Term Debt 
10,688,000
7,680,000
43,871,000
3,073,000
3,547,000
4,765,000
4,273,000
4,264,000
4,781,000
9,410,000
10,506,000
16,610,000
16,190,000
16,004,000
13,083,000
13,364,000
2,703,000
4,352,000
3,888,000
3,629,000
2,241,000
636,000
5,990,000
4,024,000
2,945,000
4,189,000
3,985,000
2,548,000
10,346,000
8,231,000
11,944,000
9,699,000
9,699,00011,944,0008,231,00010,346,0002,548,0003,985,0004,189,0002,945,0004,024,0005,990,000636,0002,241,0003,629,0003,888,0004,352,0002,703,00013,364,00013,083,00016,004,00016,190,00016,610,00010,506,0009,410,0004,781,0004,264,0004,273,0004,765,0003,547,0003,073,00043,871,0007,680,00010,688,000
       Accounts payable 
9,404,000
6,041,000
3,439,000
3,480,000
4,656,000
3,879,000
4,196,000
4,297,000
4,674,000
4,156,000
4,002,000
3,942,000
4,220,000
3,972,000
3,872,000
4,141,000
4,309,000
4,064,000
4,327,000
4,698,000
5,578,000
5,506,000
6,208,000
6,267,000
6,809,000
6,123,000
6,081,000
5,338,000
6,710,000
5,591,000
5,106,000
5,314,000
5,314,0005,106,0005,591,0006,710,0005,338,0006,081,0006,123,0006,809,0006,267,0006,208,0005,506,0005,578,0004,698,0004,327,0004,064,0004,309,0004,141,0003,872,0003,972,0004,220,0003,942,0004,002,0004,156,0004,674,0004,297,0004,196,0003,879,0004,656,0003,480,0003,439,0006,041,0009,404,000
       Other Current Liabilities 
11,023,000
11,143,000
12,604,000
10,384,000
10,435,000
8,906,000
10,838,000
11,350,000
12,212,000
12,211,000
12,120,000
10,169,000
10,027,000
7,704,000
9,939,000
10,382,000
12,076,000
12,591,000
21,690,000
26,965,000
26,732,000
26,570,000
28,882,000
26,746,000
23,438,000
20,254,000
17,314,000
16,776,000
20,541,000
18,789,000
16,411,000
19,918,000
19,918,00016,411,00018,789,00020,541,00016,776,00017,314,00020,254,00023,438,00026,746,00028,882,00026,570,00026,732,00026,965,00021,690,00012,591,00012,076,00010,382,0009,939,0007,704,00010,027,00010,169,00012,120,00012,211,00012,212,00011,350,00010,838,0008,906,00010,435,00010,384,00012,604,00011,143,00011,023,000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
66,840,000
64,245,000
68,076,000
66,738,000
67,108,000
80,647,000
79,334,000
64,836,000
63,301,000
63,941,000
61,418,000
61,343,000
61,888,000
60,411,000
58,145,000
59,151,000
57,819,000
86,228,000
86,681,000
89,419,000
88,040,000
84,399,000
83,707,000
83,707,00084,399,00088,040,00089,419,00086,681,00086,228,00057,819,00059,151,00058,145,00060,411,00061,888,00061,343,00061,418,00063,941,00063,301,00064,836,00079,334,00080,647,00067,108,00066,738,00068,076,00064,245,00066,840,000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,133,000
35,347,000
35,354,000
36,250,000
36,195,000
0
0
32,629,000
32,884,000
31,704,000
61,356,000
61,048,000
0
0
0
0
000061,048,00061,356,00031,704,00032,884,00032,629,0000036,195,00036,250,00035,354,00035,347,00037,133,0000000000000000000
       Other Liabilities 
14,509,000
13,960,000
48,325,000
48,168,000
35,999,000
34,450,000
33,267,000
32,856,000
30,519,000
29,886,000
27,050,000
30,996,000
29,736,000
30,827,000
30,118,000
29,549,000
26,589,000
27,954,000
28,587,000
25,169,000
22,637,000
26,092,000
25,911,000
25,187,000
23,348,000
0
24,554,000
0
0
0
0
0
0000024,554,000023,348,00025,187,00025,911,00026,092,00022,637,00025,169,00028,587,00027,954,00026,589,00029,549,00030,118,00030,827,00029,736,00030,996,00027,050,00029,886,00030,519,00032,856,00033,267,00034,450,00035,999,00048,168,00048,325,00013,960,00014,509,000
> Total Stockholder Equity
59,544,000
58,435,000
58,345,000
60,748,000
71,287,000
70,163,000
69,757,000
71,298,000
63,388,000
58,806,000
59,568,000
65,103,000
63,143,000
65,026,000
64,336,000
65,259,000
63,238,000
68,620,000
70,042,000
75,691,000
77,200,000
82,424,000
87,208,000
92,631,000
95,660,000
100,970,000
99,019,000
96,934,000
89,014,000
92,282,000
87,700,000
92,286,000
92,286,00087,700,00092,282,00089,014,00096,934,00099,019,000100,970,00095,660,00092,631,00087,208,00082,424,00077,200,00075,691,00070,042,00068,620,00063,238,00065,259,00064,336,00065,026,00063,143,00065,103,00059,568,00058,806,00063,388,00071,298,00069,757,00070,163,00071,287,00060,748,00058,345,00058,435,00059,544,000
   Common Stock
461,000
463,000
463,000
463,000
464,000
465,000
465,000
466,000
467,000
468,000
468,000
468,000
468,000
470,000
470,000
470,000
470,000
472,000
472,000
473,000
473,000
476,000
476,000
476,000
476,000
478,000
478,000
478,000
0
0
0
0
0000478,000478,000478,000476,000476,000476,000476,000473,000473,000472,000472,000470,000470,000470,000470,000468,000468,000468,000468,000467,000466,000465,000465,000464,000463,000463,000463,000461,000
   Retained Earnings 
71,774,000
74,847,000
74,107,000
75,043,000
85,291,000
89,961,000
89,860,000
91,995,000
89,554,000
93,388,000
94,440,000
100,113,000
97,670,000
101,000,000
100,203,000
100,284,000
96,770,000
95,158,000
96,346,000
102,252,000
103,394,000
111,193,000
116,608,000
122,967,000
125,656,000
131,102,000
128,796,000
126,411,000
118,353,000
121,318,000
116,596,000
121,059,000
121,059,000116,596,000121,318,000118,353,000126,411,000128,796,000131,102,000125,656,000122,967,000116,608,000111,193,000103,394,000102,252,00096,346,00095,158,00096,770,000100,284,000100,203,000101,000,00097,670,000100,113,00094,440,00093,388,00089,554,00091,995,00089,860,00089,961,00085,291,00075,043,00074,107,00074,847,00071,774,000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
87,680,000
87,886,000
88,161,000
88,674,000
89,002,000
89,336,000
89,973,000
90,591,000
0
0
91,359,000
91,802,000
92,153,000
92,329,000
92,496,000
0
0
0
0
000092,496,00092,329,00092,153,00091,802,00091,359,0000090,591,00089,973,00089,336,00089,002,00088,674,00088,161,00087,886,00087,680,0000000000000000
   Treasury Stock00000000000-111,361,000-111,359,000-111,356,000-111,349,000-110,988,000-110,980,000-110,978,000-111,010,0000000000000000
   Other Stockholders Equity 0000-7,826,000-8,102,000-8,290,000-8,304,000-8,226,000-7,120,000-6,158,000-5,896,000-5,648,000-4,756,000-4,637,000-11,804,000-12,820,000-13,254,000-13,064,000-11,639,000-11,801,000-11,535,000-10,923,000-11,276,000-10,417,000-10,003,000-9,402,000-9,321,000-9,164,000-10,182,000-10,594,000-11,036,000



6.3. Balance Sheets

Currency in BRL. All numbers in thousands.




6.4. Cash Flows

Currency in BRL. All numbers in thousands.




6.5. Income Statements

Currency in BRL. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in BRL. All numbers in thousands.

Gross Profit (+$)
totalRevenue58,496,000
Cost of Revenue-24,954,000
Gross Profit33,542,00033,542,000
 
Operating Income (+$)
Gross Profit33,542,000
Operating Expense-55,137,000
Operating Income3,359,000-21,595,000
 
Operating Expense (+$)
Research Development10,679,000
Selling General Administrative14,771,000
Selling And Marketing Expenses-
Operating Expense55,137,00025,450,000
 
Net Interest Income (+$)
Interest Income1,624,000
Interest Expense-2,209,000
Other Finance Cost-0
Net Interest Income-585,000
 
Pretax Income (+$)
Operating Income3,359,000
Net Interest Income-585,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,058,0005,075,000
EBIT - interestExpense = -2,209,000
2,119,000
4,328,000
Interest Expense2,209,000
Earnings Before Interest and Taxes (EBIT)-3,267,000
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax1,058,000
Tax Provision--1,115,000
Net Income From Continuing Ops2,172,0002,173,000
Net Income2,119,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,716,000585,000
 

Technical Analysis of Pfizer
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pfizer. The general trend of Pfizer is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pfizer's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pfizer Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 36.42 < 38.42 < 38.42.

The bearish price targets are: 35.64 > 35.62 > 35.29.

Tweet this
Pfizer Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pfizer Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pfizer Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pfizer Inc.

Pfizer Inc Daily Moving Average Convergence/Divergence (MACD) ChartPfizer Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pfizer Inc. The current adx is .

Pfizer Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pfizer Inc.

Pfizer Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pfizer Inc.

Pfizer Inc Daily Relative Strength Index (RSI) ChartPfizer Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pfizer Inc.

Pfizer Inc Daily Stochastic Oscillator ChartPfizer Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pfizer Inc.

Pfizer Inc Daily Commodity Channel Index (CCI) ChartPfizer Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pfizer Inc.

Pfizer Inc Daily Chande Momentum Oscillator (CMO) ChartPfizer Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pfizer Inc.

Pfizer Inc Daily Williams %R ChartPfizer Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pfizer Inc.

Pfizer Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pfizer Inc.

Pfizer Inc Daily Average True Range (ATR) ChartPfizer Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pfizer Inc.

Pfizer Inc Daily On-Balance Volume (OBV) ChartPfizer Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pfizer Inc.

Pfizer Inc Daily Money Flow Index (MFI) ChartPfizer Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pfizer Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-17ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-31RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Pfizer Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pfizer Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose36.130
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Pfizer with someone you think should read this too:
  • Are you bullish or bearish on Pfizer? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pfizer? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pfizer Inc

I send you an email if I find something interesting about Pfizer Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Pfizer Inc.

Receive notifications about Pfizer Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.